BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets
German Biotech Sets Sights On Cancer Cell Therapies
The company has already expanded into Asia and shown early clinical data from its own cell therapy programs as it acquires Kite Pharma’s neoantigen TCR R&D program and manufacturing plant.
You may also be interested in...
Booster shots could maintain Comirnaty sales in 2022, but a sharp decline is expected in follow years – and so BioNTech needs a long-term growth plan.
J&J announced strong data for its single-shot vaccine, with even stronger booster shot data to boot. Also Gilead posted strong results for outpatient use of Veklury, but it faces stiff competition, while Clover announced new data and Pfizer/BioNTech sold another 500 million vaccine doses for donation.
The company also is adding new capabilities, including a cell therapy platform, and it is investing in AI and machine learning, like fellow mRNA player and COVID-19 vaccine maker Moderna.